Navigation Links
CryoLife Posts Record Quarterly Revenues of $30.2 Million
Date:4/28/2011

ATLANTA, April 28, 2011 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the first quarter of 2011.  Revenues for the first quarter increased 2 percent to a quarter record of $30.2 million compared to $29.7 million for the first quarter of 2010.  

"We continue to post record quarterly revenues and generate strong operating cash flow, allowing us to invest in our internal product pipeline and pursue strategic business development opportunities," stated Steven G. Anderson, president and chief executive officer.  "With last year's acquisition of worldwide manufacturing and distribution rights to PerClot®, and the pending acquisition of Cardiogenesis, we are repositioning the Company for accelerated revenue and earnings growth."

Net income for the first quarter of 2011 was $1.7 million, or $0.06 per basic and fully diluted common share, compared to net income of $1.9 million, or $0.07 per basic and fully diluted common share, for the first quarter of 2010.  Excluding pretax expenses of $1.2 million related to the Company's proposed acquisition of Cardiogenesis and other business development activities, non-GAAP adjusted net income for the first quarter of 2011 was $2.4 million, or $0.09 per basic and fully diluted common share.  

Preservation service revenues for the first quarter of 2011 increased 1 percent to $15.7 million compared to $15.6 million for the first quarter of 2010.  The increase in preservation service revenues for the first quarter of 2011 was primarily due to an increase in vascular tissue average service fees and an increase in shipments of vascular tissues, largely offset by a decrease in shipments of cardiac tissues.

Product revenues, which consist primarily of sales of BioGlue®, P
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. CryoLife Launches BioGlue® Surgical Adhesive in Japan
2. CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results
3. CryoLife Announces Expiration of Go-Shop Period Related to its Proposed Acquisition of Cardiogenesis Corporation
4. CryoLife Commences Tender Offer for All Outstanding Shares of Cardiogenesis Corporation
5. CryoLife Signs Definitive Agreement to Acquire Cardiogenesis
6. CryoLife Posts Record Annual Revenues of $116.6 Million
7. CryoLife Announces Release Date and Teleconference Call Details for 2010 Fourth Quarter and Year End Financial Results
8. CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
9. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
10. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
11. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... ANGELES , Sept. 30, 2014 ... biopharmaceutical research and development company specializing in oncology, ... 2b clinical trial evaluating aldoxorubicin compared to topotecan ... (SCLC) who have relapsed or were refractory to ... the widely-used chemotherapeutic agent, doxorubicin. CytRx has received ...
(Date:9/29/2014)... et SAN DIEGO ... Company, Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) ... aujourd,hui la conclusion d,un accord de fusion définitif ... la totalité des actions ordinaires en circulation d,Ambit ... par le biais d,une offre publique d,achat qui ...
(Date:9/29/2014)... Sept. 29, 2014  Bob Pack, who lost his ... on the California Medical Association to immediately cease airing ... the San Jose Mercury News called "shamelessly deceptive" and ... wants voters to believe about the measure is wrong." ... Prop 46 requirement that doctors check California,s ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... Computer Resources of America, Inc. ... in New York City, has been awarded a ... transform, manage, and support the IT environment of ... leading provider of innovative services that enable individuals ... The contract will cover the four NY-metro locations ...
(Date:9/30/2014)... All on Four dental implants ... have received dental implants to vigilant in the fight ... The post, which can be found at http://www.newalbanyimplants.com/dr-rons-blog/ ... don’t brush and floss diligently, they could lose their ... teeth: the bone will deteriorate and the implants will ...
(Date:9/30/2014)... Ontario, Canada (PRWEB) September 30, 2014 ... diagnostic imaging services based in San Juan, Puerto ... automate their workflows. , Nivia Souffront, site ... to their facility. “We are excited to bring ... to provide better patient care and physician satisfaction ...
(Date:9/30/2014)... Westminster, Maryland (PRWEB) September 30, 2014 3M ... of acrylic very high bond tapes. 3M 5906 , ... 3M 5909 are conformable VHBs which help create the ... acrylic foam tapes are used for bonding to difficult surfaces ... , 3M VHBs 5906, 5907, 5908, and 5905 are designed ...
(Date:9/30/2014)... Doctors often order breast ultrasounds as a ... Most breast ultrasounds are done at a specialized medical imaging ... Miami . The Center for Diagnostic Imaging is now ... Most patients find ultrasounds to be more comfortable as ... have to remain perfectly still. , “We realize ...
Breaking Medicine News(10 mins):Health News:CRA Awarded Managed Services Contract for Large NYC Nonprofit 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Signet Puerto Rico Leverages PowerServer RIS/PACS/PM™ to Improve Patient Care, Cut Costs 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3Health News:Breast Ultrasounds Are a Comfortable and Convenient Option for Patients and Referring Doctors 2
... help medicine go down , , ... medicine go down" -- parents know in reality it just isn,t ... -- unique, frozen single-use packages that offer cooling, soothing relief to ... , Sucrets ICE is the newest member ...
... the definitive online resource for women who want to look fabulous ... Zuckerbrot, M.S., R.D., has assembled the most credited team of experts ... them all together on one website to offer the most on-trend, ... no cost and no calories to the consumer. , ...
... first 3 months more likely to have respiratory woes , , ... folic acid (folate) during early pregnancy may have an increased ... Folate is recommended to reduce the risk of birth defects, ... The researchers examined data on more than 32,000 children born ...
... behavior and screening have contributed greatly to the 13 percent ... playing a supporting role, according to new research from David ... first to report a long-term decline in cancer mortality, Cutler,s ... decline. Published in the fall edition of the Journal ...
... News/ -- EIN News has announced the launch of a new ... , With new advances in medicine, more and ... key components to surviving cancer. , ... about prostate cancer, its risk factors, screening procedures and drugs to ...
... Southern Research Institute -- a not-for-profit scientific organization that conducts ... discovery and development, advanced engineering, environmental and energy production -- ... Black & Veatch to help support the U.S. Department of ... , The award is expected ...
Cached Medicine News:Health News:New Sucrets(R) ICE Cools Sore Throat Pain 2Health News:SkinnyAndTheCity.com Top Experts Create the Ultimate Lifestyle Guide 2Health News:Folate in Early Pregnancy May Boost Wheezing in Baby 2Health News:Drop in cancer deaths tied primarily to gains in behavior and screening 2Health News:EIN News Introduces 'Prostate Cancer News Today'; Website Offers Information on Risk Factors, Treatment, Drugs 2Health News:Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program 2Health News:Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: